{"version":"1.0","provider_name":"Site da Brakke Consulting","provider_url":"https:\/\/brakkeconsulting.com\/pt","title":"News from Brakke Consulting","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"GltutWofEW\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/\">Mirante de Brakke 24 de maio de 2024<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-may-24-2024\/embed\/#?secret=GltutWofEW\" width=\"600\" height=\"338\" title=\"\u201cBrakke Viewpoint 24 de maio de 2024\u201d - Site da Brakke Consulting\" data-secret=\"GltutWofEW\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/brakkeconsulting.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>","description":"This week we published the latest edition of our annual Pain Management Products report.\u00a0 It\u2019s a fascinating time in the market segment, thanks to the launch last November of Zoetis\u2019 Librela, a monthly monoclonal antibody injection for treating osteoarthritis; and that of Solensia \u2013 the feline equivalent \u2013 in late 2022. This new class of pain management drugs has the potential to revolutionize the treatment of chronic pain.\u00a0 Most veterinarians are already using monoclonal antibodies in their osteoarthritis patients. But how often are they reaching for them?\u00a0 Are they stand-alone treatments, or part of a multi-modal protocol? Will Librela completely replace the use of NSAIDs in treating osteoarthritis? Is Solensia creating a new market, much like Rimadyl did so when it was launched in the 1990\u2019s? Our Pain Management Product report answers these questions and more, with direct feedback from our 350-veterinarian survey as well as PIMS-based dispensing data as of April 2024. If your company is part of the companion animal pain management market, you won\u2019t want to miss out on the valuable insights in this report. Lynn Fondon"}